Drug Trial Radar · NCT06879041
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
136
Planned (sponsor's estimate)
Start
Mar 10, 2025
Primary completion
Apr 16, 2029
Study completion Apr 16, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Mar 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Conditions
- Metastatic Castration-Resistant Prostate Cancer
Interventions
AZD2287Drug
Participants will receive AZD2287
AZD2275Drug
Participants will receive AZD2275
AZD2284Drug
Participants will receive AZD2284
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse event (AEs)Time frame: Part A: Up to Day 28; Part B: Up to 5 years
- Number of participants with Dose Limiting Toxicities (DLTs)Time frame: Part B: Up to 84 days of receiving AZD2284
- Estimates of residence timeTime frame: Part A: Up to 8 days after a dose of AZD2287
- Absorbed radiation doses for AZD2287 and AZD2284Time frame: Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287
- Compare organ uptake of AZD2287 with and without pre-dose administration of AZD2275Time frame: Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287
- Tumor uptake of AZD2287 in selected regions of interest on SPECT/CT and/or planar imagesTime frame: Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287
Locations
16 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
Palo Alto, California · Not yet recruiting
Research Site
San Diego, California · Not yet recruiting
Research Site
Miami, Florida · Recruiting
Research Site
Tampa, Florida · Recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Metairie, Louisiana · Not yet recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Rochester, Minnesota · Not yet recruiting
Research Site
Omaha, Nebraska · Recruiting
Research Site
New York, New York · Not yet recruiting
Research Site
Cleveland, Ohio · Not yet recruiting
Research Site
Portland, Oregon · Not yet recruiting
Research Site
East Melbourne, Australia · Recruiting
Research Site
CapeTown, South Africa · Not yet recruiting
Research Site
Durban, South Africa · Withdrawn
Research Site
Pretoria, South Africa · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.